1. Home
  2. JELD vs EOLS Comparison

JELD vs EOLS Comparison

Compare JELD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JELD
  • EOLS
  • Stock Information
  • Founded
  • JELD 1960
  • EOLS 2012
  • Country
  • JELD United States
  • EOLS United States
  • Employees
  • JELD 17700
  • EOLS N/A
  • Industry
  • JELD Forest Products
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • JELD Basic Materials
  • EOLS Health Care
  • Exchange
  • JELD Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • JELD 707.4M
  • EOLS 787.7M
  • IPO Year
  • JELD 2017
  • EOLS 2018
  • Fundamental
  • Price
  • JELD $8.36
  • EOLS $10.85
  • Analyst Decision
  • JELD Hold
  • EOLS Strong Buy
  • Analyst Count
  • JELD 9
  • EOLS 6
  • Target Price
  • JELD $13.63
  • EOLS $22.60
  • AVG Volume (30 Days)
  • JELD 609.2K
  • EOLS 520.6K
  • Earning Date
  • JELD 02-18-2025
  • EOLS 11-06-2024
  • Dividend Yield
  • JELD N/A
  • EOLS N/A
  • EPS Growth
  • JELD N/A
  • EOLS N/A
  • EPS
  • JELD N/A
  • EOLS N/A
  • Revenue
  • JELD $3,900,923,000.00
  • EOLS $248,326,000.00
  • Revenue This Year
  • JELD N/A
  • EOLS $33.43
  • Revenue Next Year
  • JELD N/A
  • EOLS $32.44
  • P/E Ratio
  • JELD N/A
  • EOLS N/A
  • Revenue Growth
  • JELD N/A
  • EOLS 34.42
  • 52 Week Low
  • JELD $8.15
  • EOLS $9.80
  • 52 Week High
  • JELD $21.75
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • JELD 21.98
  • EOLS 28.02
  • Support Level
  • JELD $8.30
  • EOLS $10.63
  • Resistance Level
  • JELD $10.79
  • EOLS $11.83
  • Average True Range (ATR)
  • JELD 0.40
  • EOLS 0.46
  • MACD
  • JELD -0.16
  • EOLS -0.05
  • Stochastic Oscillator
  • JELD 7.45
  • EOLS 9.32

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: